<p>Abivax SA 赞助的 ADR（NASDAQ:ABVX - 获取免费报告）在周一的交易中出现了异常高的交易量，此前摩根士丹利将该股票的目标价从 101.00 美元上调至 145.00 美元。摩根士丹利目前对该股票给予了增持评级。在午盘交易中，约有 2,646,946 股易手，比前一交易日的 2,126,757 股交易量增加了 24%。该股票最后交易价格为 120.2010 美元，之前收盘价为 114.40 美元。</p>
<p>其他一些研究分析师也对该股票发布了报告。Citizens Jmp 将 Abivax 的目标价从 114.00 美元上调至 131.00 美元，并在 12 月 16 日的研究报告中给予该公司 “市场表现优于大盘” 的评级。巴克莱在 10 月 13 日的研究报告中开始覆盖 Abivax，给予 “增持” 评级和 142.00 美元的目标价。JMP Securities 在 9 月 25 日的研究报告中将 Abivax 的目标价从 95.00 美元上调至 114.00 美元，并给予该公司 “市场表现优于大盘” 的评级。华尔街禅在 12 月 13 日的研究报告中将 Abivax 的评级从 “持有” 下调至 “卖出”。最后，Wolfe Research 在 11 月 6 日的报告中将 Abivax 的评级上调至 “强烈买入”。一位投资分析师给予该股票 “强烈买入” 评级，十一位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 135.08 美元。</p>
<p><strong>查看我们最新的 ABVX 股票分析</strong></p>
<h2>Abivax 的机构交易</h2>
<p>机构投资者和对冲基金最近买卖了该股票的股份。EverSource Wealth Advisors LLC 在第三季度将其在 Abivax 的持股增加了 4,612.5%。EverSource Wealth Advisors LLC 目前拥有 377 股该公司的股票，价值 32,000 美元，此前在此期间又购买了 369 股。First Horizon Corp 在第三季度购买了 Abivax 的新头寸，价值约 36,000 美元。Union Bancaire Privee UBP SA 在第四季度收购了 Abivax 的新股份，价值 67,000 美元。Hantz Financial Services Inc. 在第三季度购买了 Abivax 的新股份，价值 52,000 美元。最后，Gordian Capital Singapore Pte Ltd 在第三季度收购了 Abivax 的新股份，价值 76,000 美元。机构投资者和对冲基金持有该公司 47.91% 的股份。</p>
<h2>Abivax 股票上涨 5.6%</h2>
<p>该公司的市值为 94.1 亿美元，市盈率为 -28.42，贝塔值为 0.68。该公司的债务与股本比率为 0.03，流动比率为 7.86，速动比率为 7.86。该业务的 50 日移动平均价格为 120.17 美元，200 日移动平均价格为 85.64 美元。</p>
<p>Abivax（NASDAQ:ABVX - 获取免费报告）在 12 月 15 日星期一发布了其财报。该公司报告本季度每股收益为（2.46 美元）。该业务在本季度的收入为（492 万美元）。分析师预计 Abivax SA 赞助的 ADR 本财年将发布 -2.83 的每股收益。</p>
<h2>关于 Abivax</h2>
<p>（获取免费报告）</p>
<p>Abivax 成立于 2013 年，总部位于法国巴黎，是一家临床阶段的生物制药公司，专注于发现和开发用于治疗慢性炎症性疾病和病毒感染的新疗法。该公司的技术平台针对宿主 RNA 生物发生，以调节关键免疫通路，提供旨在疾病修饰和改善安全性特征的差异化方法。</p>
<p>Abivax 的主要临床资产 obefazimod（ABX464）正在评估用于溃疡性结肠炎和其他炎症性疾病。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票</li>
<li>你的银行账户不再安全</li>
<li>开火正式开始……</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护你的财富</li>
<li>在将 AI 数据中心送入轨道的竞赛中早期进入的参与者</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Abivax 吗？</h2>
<p>在你考虑 Abivax 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Abivax 并不在名单上。</p>
<p>虽然 Abivax 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

ABVX

<p>Abivax（纳斯达克代码：ABVX）在摩根士丹利将其目标价从 101 美元上调至 145 美元并维持 “增持” 评级后，交易量显著增加。约有 265 万股被交易，较前一交易日增加了 24%。其他分析师也上调了他们的目标价，普遍评级为 “适度买入”，目标价为 135.08 美元。该股票上涨了 5.6%，市值为 94.1 亿美元。Abivax 专注于开发慢性炎症疾病和病毒感染的治疗方案</p>

<p>Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) saw unusually-high trading volume on Monday after Morgan Stanley raised their price target on the stock from $101.00 to $145.00. Morgan Stanley currently has an overweight rating on the stock. Approximately 2,646,946 shares changed hands during mid-day trading, an increase of 24% from the previous session's volume of 2,126,757 shares.The stock last traded at $120.2010 and had previously closed at $114.40.</p>
<div class="lb-trans"><p>Abivax SA 赞助的 ADR（NASDAQ:ABVX - 获取免费报告）在周一的交易中出现了异常高的交易量，此前摩根士丹利将该股票的目标价从 101.00 美元上调至 145.00 美元。摩根士丹利目前对该股票给予了增持评级。在午盘交易中，约有 2,646,946 股易手，比前一交易日的 2,126,757 股交易量增加了 24%。该股票最后交易价格为 120.2010 美元，之前收盘价为 114.40 美元。</p>
</div><p>A number of other research analysts have also issued reports on the stock. Citizens Jmp boosted their target price on shares of Abivax from $114.00 to $131.00 and gave the company a &#34;market outperform&#34; rating in a research note on Tuesday, December 16th. Barclays assumed coverage on Abivax in a research report on Monday, October 13th. They set an &#34;overweight&#34; rating and a $142.00 price objective for the company. JMP Securities raised their target price on Abivax from $95.00 to $114.00 and gave the company a &#34;market outperform&#34; rating in a research report on Thursday, September 25th. Wall Street Zen lowered Abivax from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, December 13th. Finally, Wolfe Research raised Abivax to a &#34;strong-buy&#34; rating in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $135.08.</p>
<div class="lb-trans"><p>其他一些研究分析师也对该股票发布了报告。Citizens Jmp 将 Abivax 的目标价从 114.00 美元上调至 131.00 美元，并在 12 月 16 日的研究报告中给予该公司 “市场表现优于大盘” 的评级。巴克莱在 10 月 13 日的研究报告中开始覆盖 Abivax，给予 “增持” 评级和 142.00 美元的目标价。JMP Securities 在 9 月 25 日的研究报告中将 Abivax 的目标价从 95.00 美元上调至 114.00 美元，并给予该公司 “市场表现优于大盘” 的评级。华尔街禅在 12 月 13 日的研究报告中将 Abivax 的评级从 “持有” 下调至 “卖出”。最后，Wolfe Research 在 11 月 6 日的报告中将 Abivax 的评级上调至 “强烈买入”。一位投资分析师给予该股票 “强烈买入” 评级，十一位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 135.08 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on ABVX</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 ABVX 股票分析</strong></p>
</div><h2>Institutional Trading of Abivax</h2>
<div class="lb-trans"><h2>Abivax 的机构交易</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC boosted its holdings in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock worth $32,000 after buying an additional 369 shares during the period. First Horizon Corp purchased a new position in Abivax during the 3rd quarter worth approximately $36,000. Union Bancaire Privee UBP SA acquired a new stake in Abivax during the 4th quarter valued at $67,000. Hantz Financial Services Inc. purchased a new stake in shares of Abivax in the third quarter valued at $52,000. Finally, Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Abivax in the third quarter worth $76,000. Institutional investors and hedge funds own 47.91% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买卖了该股票的股份。EverSource Wealth Advisors LLC 在第三季度将其在 Abivax 的持股增加了 4,612.5%。EverSource Wealth Advisors LLC 目前拥有 377 股该公司的股票，价值 32,000 美元，此前在此期间又购买了 369 股。First Horizon Corp 在第三季度购买了 Abivax 的新头寸，价值约 36,000 美元。Union Bancaire Privee UBP SA 在第四季度收购了 Abivax 的新股份，价值 67,000 美元。Hantz Financial Services Inc. 在第三季度购买了 Abivax 的新股份，价值 52,000 美元。最后，Gordian Capital Singapore Pte Ltd 在第三季度收购了 Abivax 的新股份，价值 76,000 美元。机构投资者和对冲基金持有该公司 47.91% 的股份。</p>
</div><h2>Abivax Stock Up 5.6%</h2>
<div class="lb-trans"><h2>Abivax 股票上涨 5.6%</h2>
</div><p>The firm has a market cap of $9.41 billion, a PE ratio of -28.42 and a beta of 0.68. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86. The business has a fifty day moving average price of $120.17 and a two-hundred day moving average price of $85.64.</p>
<div class="lb-trans"><p>该公司的市值为 94.1 亿美元，市盈率为 -28.42，贝塔值为 0.68。该公司的债务与股本比率为 0.03，流动比率为 7.86，速动比率为 7.86。该业务的 50 日移动平均价格为 120.17 美元，200 日移动平均价格为 85.64 美元。</p>
</div><p>Abivax (NASDAQ:ABVX - Get Free Report) last released its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The business had revenue of ($4.92) million during the quarter. On average, analysts anticipate that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Abivax（NASDAQ:ABVX - 获取免费报告）在 12 月 15 日星期一发布了其财报。该公司报告本季度每股收益为（2.46 美元）。该业务在本季度的收入为（492 万美元）。分析师预计 Abivax SA 赞助的 ADR 本财年将发布 -2.83 的每股收益。</p>
</div><h2>About Abivax</h2>
<div class="lb-trans"><h2>关于 Abivax</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.</p>
<div class="lb-trans"><p>Abivax 成立于 2013 年，总部位于法国巴黎，是一家临床阶段的生物制药公司，专注于发现和开发用于治疗慢性炎症性疾病和病毒感染的新疗法。该公司的技术平台针对宿主 RNA 生物发生，以调节关键免疫通路，提供旨在疾病修饰和改善安全性特征的差异化方法。</p>
</div><p>Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.</p>
<div class="lb-trans"><p>Abivax 的主要临床资产 obefazimod（ABX464）正在评估用于溃疡性结肠炎和其他炎症性疾病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Abivax</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Shots officially fired…</li>
<li>Do not delete, read immediately</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Early-Entry Player in the Race to Put AI Data Centers in Orbit</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票</li>
<li>你的银行账户不再安全</li>
<li>开火正式开始……</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护你的财富</li>
<li>在将 AI 数据中心送入轨道的竞赛中早期进入的参与者</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abivax Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Abivax 吗？</h2>
</div><p>Before you consider Abivax, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Abivax 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Abivax 并不在名单上。</p>
</div><p>While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Abivax 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Abivax（NASDAQ:ABVX）在分析师上调评级后，交易量显著增加